“I don’t foresee us going back to the way things were anytime soon.”
Why Indiana Doesn’t Want This Indianapolis Lab’s Coronavirus Test Kits
“Our first priority is our community, our city, and the state.”
Indy’s Bicentennial: A Year Of Celebrations
Toast to the town.
Mike Dalton, Eli Lilly Chemist
At the pharmaceutical giant, Dalton’s job is to thwart counterfeiters, who can be a real pill.
Eli Lilly’s Hazy Memory
A century ago, Eli Lilly and Company grew one of the nation’s largest cannabis farms to supply a variety of pharmaceuticals. Why does the drug maker seem determined to conceal the details of that history?
The Unblinding: Has Lilly Solved the Alzheimer’s Puzzle? — An Epilogue
The search continues.
December Foodie: Pia Urban Cafe’s Maria Cartagena
Look behind the counter for the truest sign of Cartagena’s mission: Her team includes graduates of the Wheeler Mission residential program.
The Unblinding: Has Lilly Solved The Alzheimer’s Puzzle?
Eli Lilly and Company has spent three decades and $3 billion in an Ahab-like quest to develop the world’s first effective drug to treat Alzheimer’s disease.
Culture Warriors: LGBT Battlefield
“RFRA was embarrassing, but Pence hasn’t won elections by championing LGBT causes. And he still wields the veto pen, which is mighty indeed.”
Life after Zyprexa: the Future of Eli Lilly and Company
“We want high quality of life as long as possible, don’t we?” says Lilly executive Jan Lundberg. “Many of our current diseases are chronic, and they accumulate with age, so there are major demands coming from the aging population.”
With thousands of medical success stories and billions in revenue, officials at Lilly are still celebrating the success of Zyprexa. But its troubled path reveals volumes about how difficult bringing even an approved medication to market can turn out to be.